Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Algernon Pharmaceuticals ( (TSE:AGN) ) has issued an update.
Algernon Pharmaceuticals has announced a notice of allowance from the USPTO for its lead drug candidate, Repirinast, for treating chronic kidney disease. This patent approval, valid until 2038, supports their intellectual property strategy and positions the company strongly in the CKD market, which is expected to grow significantly by 2030.
More about Algernon Pharmaceuticals
Algernon Pharmaceuticals Inc. is a clinical stage pharmaceutical development company focused on repurposing drugs for new therapeutic indications. The company is involved in developing treatments for chronic kidney disease and other health conditions, with a strategic focus on securing intellectual property protection for their drug candidates.
YTD Price Performance: 2.04%
Average Trading Volume: 5,341
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $961.6K
See more data about AGN stock on TipRanks’ Stock Analysis page.
